|
DE3572982D1
(en)
|
1984-03-06 |
1989-10-19 |
Takeda Chemical Industries Ltd |
Chemically modified lymphokine and production thereof
|
|
US4766106A
(en)
|
1985-06-26 |
1988-08-23 |
Cetus Corporation |
Solubilization of proteins for pharmaceutical compositions using polymer conjugation
|
|
US5206344A
(en)
|
1985-06-26 |
1993-04-27 |
Cetus Oncology Corporation |
Interleukin-2 muteins and polymer conjugation thereof
|
|
US4704692A
(en)
|
1986-09-02 |
1987-11-03 |
Ladner Robert C |
Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・２・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
|
US5128257A
(en)
|
1987-08-31 |
1992-07-07 |
Baer Bradford W |
Electroporation apparatus and process
|
|
DE68925030T2
(de)
|
1988-01-21 |
1996-07-25 |
Massachusetts Inst Technology |
Molekültransport durch gewebe mit der verwendung von elektroporation.
|
|
US6780613B1
(en)
|
1988-10-28 |
2004-08-24 |
Genentech, Inc. |
Growth hormone variants
|
|
WO1990006952A1
(fr)
|
1988-12-22 |
1990-06-28 |
Kirin-Amgen, Inc. |
Facteur de stimulation de colonies de granulocytes modifies chimiquement
|
|
US5089261A
(en)
|
1989-01-23 |
1992-02-18 |
Cetus Corporation |
Preparation of a polymer/interleukin-2 conjugate
|
|
US4902502A
(en)
|
1989-01-23 |
1990-02-20 |
Cetus Corporation |
Preparation of a polymer/interleukin-2 conjugate
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
US5279833A
(en)
|
1990-04-04 |
1994-01-18 |
Yale University |
Liposomal transfection of nucleic acids into animal cells
|
|
CA2019758C
(en)
|
1990-06-25 |
2001-09-04 |
Kevin L. Firth |
Improved electroporation device and method
|
|
US5137817A
(en)
|
1990-10-05 |
1992-08-11 |
Amoco Corporation |
Apparatus and method for electroporation
|
|
US5173158A
(en)
|
1991-07-22 |
1992-12-22 |
Schmukler Robert E |
Apparatus and methods for electroporation and electrofusion
|
|
ATE207080T1
(de)
|
1991-11-25 |
2001-11-15 |
Enzon Inc |
Multivalente antigen-bindende proteine
|
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
|
US5304120A
(en)
|
1992-07-01 |
1994-04-19 |
Btx Inc. |
Electroporation method and apparatus for insertion of drugs and genes into endothelial cells
|
|
US5273525A
(en)
|
1992-08-13 |
1993-12-28 |
Btx Inc. |
Injection and electroporation apparatus for drug and gene delivery
|
|
US5318514A
(en)
|
1992-08-17 |
1994-06-07 |
Btx, Inc. |
Applicator for the electroporation of drugs and genes into surface cells
|
|
GB9317380D0
(en)
|
1993-08-20 |
1993-10-06 |
Therexsys Ltd |
Transfection process
|
|
US6989434B1
(en)
|
1994-02-11 |
2006-01-24 |
Invitrogen Corporation |
Reagents for intracellular delivery of macromolecules
|
|
JPH11505505A
(ja)
|
1994-06-27 |
1999-05-21 |
ザ・ジョンズ・ホプキンス・ユニバーシティー |
ターゲッティングされた遺伝子輸送システム
|
|
US5908635A
(en)
|
1994-08-05 |
1999-06-01 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method for the liposomal delivery of nucleic acids
|
|
US5484720A
(en)
|
1994-09-08 |
1996-01-16 |
Genentech, Inc. |
Methods for calcium phosphate transfection
|
|
GB9422383D0
(en)
|
1994-11-05 |
1995-01-04 |
Wellcome Found |
Antibodies
|
|
US5830430A
(en)
|
1995-02-21 |
1998-11-03 |
Imarx Pharmaceutical Corp. |
Cationic lipids and the use thereof
|
|
US6096871A
(en)
|
1995-04-14 |
2000-08-01 |
Genentech, Inc. |
Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
|
|
US5739277A
(en)
|
1995-04-14 |
1998-04-14 |
Genentech Inc. |
Altered polypeptides with increased half-life
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US5981501A
(en)
|
1995-06-07 |
1999-11-09 |
Inex Pharmaceuticals Corp. |
Methods for encapsulating plasmids in lipid bilayers
|
|
US6010613A
(en)
|
1995-12-08 |
2000-01-04 |
Cyto Pulse Sciences, Inc. |
Method of treating materials with pulsed electrical fields
|
|
DE69738522T2
(de)
|
1996-08-02 |
2009-04-02 |
Bristol-Myers Squibb Co. |
Ein verfahren zur inhibierung immunglobulininduzierter toxizität aufgrund von der verwendung von immunoglobinen in therapie und in vivo diagnostik
|
|
WO1998023289A1
(en)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
MODULATION OF IgG BINDING TO FcRn
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
ATE466948T1
(de)
|
1997-03-11 |
2010-05-15 |
Univ Minnesota |
Dns-basiertes transposon-system für die einführung von nucleinsäure in die dns einer zelle
|
|
GB9710809D0
(en)
|
1997-05-23 |
1997-07-23 |
Medical Res Council |
Nucleic acid binding proteins
|
|
US6475994B2
(en)
|
1998-01-07 |
2002-11-05 |
Donald A. Tomalia |
Method and articles for transfection of genetic material
|
|
ES2341926T3
(es)
|
1998-03-02 |
2010-06-29 |
Massachusetts Institute Of Technology |
Poliproteinas con dedos de cinc que tienen enlazadores mejorados.
|
|
ATE375365T1
(de)
|
1998-04-02 |
2007-10-15 |
Genentech Inc |
Antikörper varianten und fragmente davon
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
|
US6242195B1
(en)
|
1998-04-02 |
2001-06-05 |
Genentech, Inc. |
Methods for determining binding of an analyte to a receptor
|
|
DK1071700T3
(da)
|
1998-04-20 |
2010-06-07 |
Glycart Biotechnology Ag |
Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
EP1105427A2
(en)
|
1998-08-17 |
2001-06-13 |
Abgenix, Inc. |
Generation of modified molecules with increased serum half-lives
|
|
EP1006183A1
(en)
|
1998-12-03 |
2000-06-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Recombinant soluble Fc receptors
|
|
US7109003B2
(en)
|
1998-12-23 |
2006-09-19 |
Abgenix, Inc. |
Methods for expressing and recovering human monoclonal antibodies to CTLA-4
|
|
US7013219B2
(en)
|
1999-01-12 |
2006-03-14 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
|
US6534261B1
(en)
|
1999-01-12 |
2003-03-18 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
PL209392B1
(pl)
|
1999-01-15 |
2011-08-31 |
Genentech Inc |
Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
|
|
US7030215B2
(en)
|
1999-03-24 |
2006-04-18 |
Sangamo Biosciences, Inc. |
Position dependent recognition of GNN nucleotide triplets by zinc fingers
|
|
US20030104526A1
(en)
|
1999-03-24 |
2003-06-05 |
Qiang Liu |
Position dependent recognition of GNN nucleotide triplets by zinc fingers
|
|
US6794136B1
(en)
|
2000-11-20 |
2004-09-21 |
Sangamo Biosciences, Inc. |
Iterative optimization in the design of binding proteins
|
|
IL129299A0
(en)
|
1999-03-31 |
2000-02-17 |
Mor Research Applic Ltd |
Monoclonal antibodies antigens and diagnosis of malignant diseases
|
|
CA2704600C
(en)
|
1999-04-09 |
2016-10-25 |
Kyowa Kirin Co., Ltd. |
A method for producing antibodies with increased adcc activity
|
|
US6946129B1
(en)
|
1999-06-08 |
2005-09-20 |
Seattle Genetics, Inc. |
Recombinant anti-CD40 antibody and uses thereof
|
|
EP1212422B1
(en)
|
1999-08-24 |
2007-02-21 |
Medarex, Inc. |
Human ctla-4 antibodies and their uses
|
|
DK1234031T3
(en)
|
1999-11-30 |
2017-07-03 |
Mayo Foundation |
B7-H1, AN UNKNOWN IMMUNE REGULATORY MOLECULE
|
|
US7189705B2
(en)
|
2000-04-20 |
2007-03-13 |
The University Of British Columbia |
Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers
|
|
US6627442B1
(en)
|
2000-08-31 |
2003-09-30 |
Virxsys Corporation |
Methods for stable transduction of cells with hiv-derived viral vectors
|
|
CN1507357A
(zh)
|
2000-10-31 |
2004-06-23 |
PRҩƷ����˾ |
提高生物活性分子传递的方法和组合物
|
|
GB0029407D0
(en)
|
2000-12-01 |
2001-01-17 |
Affitech As |
Product
|
|
US7083784B2
(en)
|
2000-12-12 |
2006-08-01 |
Medimmune, Inc. |
Molecules with extended half-lives, compositions and uses thereof
|
|
CA2463879C
(en)
|
2001-10-25 |
2012-12-04 |
Genentech, Inc. |
Glycoprotein compositions
|
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
|
US20040002587A1
(en)
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
JP2006502091A
(ja)
|
2002-03-01 |
2006-01-19 |
イミューノメディクス、インコーポレイテッド |
クリアランス速度を高めるための二重特異性抗体点変異
|
|
BR0309145A
(pt)
|
2002-04-09 |
2005-02-01 |
Kyowa Hakko Kogyo Kk |
Células das quais o genoma é modificado
|
|
IL149820A0
(en)
|
2002-05-23 |
2002-11-10 |
Curetech Ltd |
Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
|
|
AU2003281200A1
(en)
|
2002-07-03 |
2004-01-23 |
Tasuku Honjo |
Immunopotentiating compositions
|
|
DK1545613T3
(da)
|
2002-07-31 |
2011-11-14 |
Seattle Genetics Inc |
Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
|
|
DK1534335T4
(en)
|
2002-08-14 |
2015-10-05 |
Macrogenics Inc |
FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF
|
|
ES2377318T3
(es)
|
2002-09-06 |
2012-03-26 |
Cerulean Pharma Inc. |
Polímeros a base de ciclodextrina para el suministro de los agentes terapéuticos enlazados covalentemente a ellos
|
|
EP1553975B8
(en)
|
2002-09-27 |
2023-04-12 |
Xencor, Inc. |
Optimized fc variants and methods for their generation
|
|
DK1562972T3
(da)
|
2002-10-15 |
2010-12-06 |
Facet Biotech Corp |
Modifikation af FcRn-bindingsaffiniteter eller serumhalveringstider for antistoffer ved mutagenese
|
|
CN101899114A
(zh)
|
2002-12-23 |
2010-12-01 |
惠氏公司 |
抗pd-1抗体及其用途
|
|
CA2512729C
(en)
|
2003-01-09 |
2014-09-16 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant fc regions and methods of using same
|
|
GB0324368D0
(en)
|
2003-10-17 |
2003-11-19 |
Univ Cambridge Tech |
Polypeptides including modified constant regions
|
|
EP2478912B1
(en)
|
2003-11-06 |
2016-08-31 |
Seattle Genetics, Inc. |
Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
|
|
EP1697520A2
(en)
|
2003-12-22 |
2006-09-06 |
Xencor, Inc. |
Fc polypeptides with novel fc ligand binding sites
|
|
SI1706424T1
(sl)
|
2004-01-12 |
2010-01-29 |
Applied Molecular Evolution |
Variante fc regij
|
|
EP1737890A2
(en)
|
2004-03-24 |
2007-01-03 |
Xencor, Inc. |
Immunoglobulin variants outside the fc region
|
|
WO2005123780A2
(en)
|
2004-04-09 |
2005-12-29 |
Protein Design Labs, Inc. |
Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
US7691962B2
(en)
|
2004-05-19 |
2010-04-06 |
Medarex, Inc. |
Chemical linkers and conjugates thereof
|
|
WO2006085967A2
(en)
|
2004-07-09 |
2006-08-17 |
Xencor, Inc. |
OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
|
|
EP2471813B1
(en)
|
2004-07-15 |
2014-12-31 |
Xencor, Inc. |
Optimized Fc variants
|
|
WO2006047350A2
(en)
|
2004-10-21 |
2006-05-04 |
Xencor, Inc. |
IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
|
|
US9244059B2
(en)
|
2007-04-30 |
2016-01-26 |
Immutep Parc Club Orsay |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
|
US20090304719A1
(en)
|
2007-08-22 |
2009-12-10 |
Patrick Daugherty |
Activatable binding polypeptides and methods of identification and use thereof
|
|
WO2009032954A1
(en)
|
2007-09-04 |
2009-03-12 |
The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Deletions in domain ii of pseudomonas exotoxin a that reduce non-specific toxicity
|
|
AU2009290544B2
(en)
|
2008-09-12 |
2015-07-16 |
Oxford University Innovation Limited |
PD-1 specific antibodies and uses thereof
|
|
US8552154B2
(en)
|
2008-09-26 |
2013-10-08 |
Emory University |
Anti-PD-L1 antibodies and uses therefor
|
|
US9283184B2
(en)
|
2008-11-24 |
2016-03-15 |
Massachusetts Institute Of Technology |
Methods and compositions for localized agent delivery
|
|
EP3255060A1
(en)
|
2008-12-09 |
2017-12-13 |
F. Hoffmann-La Roche AG |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
|
WO2010126766A1
(en)
|
2009-04-30 |
2010-11-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Inducible interleukin-12
|
|
US8586526B2
(en)
|
2010-05-17 |
2013-11-19 |
Sangamo Biosciences, Inc. |
DNA-binding proteins and uses thereof
|
|
PL2504364T3
(pl)
|
2009-11-24 |
2017-12-29 |
Medimmune Limited |
Ukierunkowane środki wiążące przeciwko B7-H1
|
|
EP2545078A1
(en)
|
2010-03-11 |
2013-01-16 |
UCB Pharma, S.A. |
Pd-1 antibody
|
|
AU2011265733B2
(en)
|
2010-06-14 |
2014-04-17 |
Iowa State University Research Foundation, Inc. |
Nuclease activity of TAL effector and Foki fusion protein
|
|
WO2011159877A2
(en)
|
2010-06-18 |
2011-12-22 |
The Brigham And Women's Hospital, Inc. |
Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
|
|
US8507222B2
(en)
|
2010-09-21 |
2013-08-13 |
Altor Bioscience Corporation |
Multimeric IL-15 soluble fusion molecules and methods of making and using same
|
|
WO2012065086A1
(en)
|
2010-11-12 |
2012-05-18 |
Nektar Therapeutics |
Conjugates of an il-2 moiety and a polymer
|
|
CA3111953C
(en)
|
2011-04-05 |
2023-10-24 |
Cellectis |
Method for the generation of compact tale-nucleases and uses thereof
|
|
JP6072771B2
(ja)
|
2011-04-20 |
2017-02-01 |
メディミューン，エルエルシー |
Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
|
|
ES2709654T3
(es)
|
2011-04-29 |
2019-04-17 |
Apexigen Inc |
Anticuerpos anti-CD40 y métodos de uso
|
|
WO2013006490A2
(en)
|
2011-07-01 |
2013-01-10 |
Cellerant Therapeutics, Inc. |
Antibodies that specifically bind to tim3
|
|
CA2840018C
(en)
|
2011-07-24 |
2019-07-16 |
Curetech Ltd. |
Variants of humanized immunomodulatory monoclonal antibodies
|
|
CN103946952A
(zh)
|
2011-09-16 |
2014-07-23 |
宾夕法尼亚大学董事会 |
用于治疗癌症的rna改造的t细胞
|
|
PT2768942T
(pt)
|
2011-10-17 |
2020-01-21 |
Massachusetts Inst Technology |
Entrega intracelular
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
BR112014029417B1
(pt)
|
2012-05-25 |
2023-03-07 |
Cellectis |
Método ex vivo para a preparação de células t para imunoterapia
|
|
KR20220084444A
(ko)
|
2012-05-31 |
2022-06-21 |
소렌토 쎄라퓨틱스, 인코포레이티드 |
Pd-l1에 결합하는 항원 결합 단백질
|
|
WO2013182910A2
(en)
|
2012-06-05 |
2013-12-12 |
Cellectis |
New transcription activator-like effector (tale) fusion protein
|
|
US9156897B2
(en)
|
2012-06-08 |
2015-10-13 |
Alkermes, Inc. |
Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
|
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
|
WO2014093655A2
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
|
|
CN113355357B
(zh)
|
2012-12-12 |
2024-12-03 |
布罗德研究所有限公司 |
对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
|
|
US20140310830A1
(en)
|
2012-12-12 |
2014-10-16 |
Feng Zhang |
CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
|
|
IL239344B2
(en)
|
2012-12-12 |
2024-06-01 |
Broad Inst Inc |
Systems engineering, methods and optimal guiding components for sequence manipulation
|
|
EP2840140B2
(en)
|
2012-12-12 |
2023-02-22 |
The Broad Institute, Inc. |
Crispr-Cas based method for mutation of prokaryotic cells
|
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
|
US11311575B2
(en)
|
2013-05-13 |
2022-04-26 |
Cellectis |
Methods for engineering highly active T cell for immunotherapy
|
|
EP3004339B1
(en)
|
2013-05-29 |
2021-07-07 |
Cellectis |
New compact scaffold of cas9 in the type ii crispr system
|
|
CN112552401B
(zh)
|
2013-09-13 |
2023-08-25 |
广州百济神州生物制药有限公司 |
抗pd1抗体及其作为治疗剂与诊断剂的用途
|
|
CA3191031A1
(en)
|
2013-09-27 |
2015-04-02 |
Massachusetts Institute Of Technology |
Carrier-free biologically-active protein nanostructures
|
|
EP3690044B1
(en)
|
2014-02-11 |
2024-01-10 |
The Regents of the University of Colorado, a body corporate |
Crispr enabled multiplexed genome engineering
|
|
JP6681837B2
(ja)
|
2014-03-11 |
2020-04-15 |
セレクティスＣｅｌｌｅｃｔｉｓ |
同種移植に適合するｔ細胞を作製するための方法
|
|
EP3197911A4
(en)
*
|
2014-09-22 |
2018-06-20 |
Intrexon Corporation |
Improved therapeutic control of heterodimeric and single chain forms of interleukin-12
|
|
FI3277321T3
(fi)
|
2015-04-01 |
2024-10-31 |
Anaptysbio Inc |
T-soluimmunoglobuliinia ja musiiniproteiini 3:a (tim-3) vastaan suunnattuja vasta-aineita
|
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
|
AU2016289530B2
(en)
|
2015-07-09 |
2021-05-06 |
Massachusetts Institute Of Technology |
Delivery of materials to anucleate cells
|
|
EP3344575B1
(en)
|
2015-09-04 |
2020-04-15 |
SQZ Biotechnologies Company |
Intracellular delivery of biomolecules to cells comprising a cell wall
|
|
EP3347026A4
(en)
*
|
2015-09-09 |
2019-05-08 |
Seattle Children's Hospital (DBA Seattle Children's Research Institute) |
GENEMANIPULATION OF MACROPHAGES FOR IMMUNOTHERAPY
|
|
CN120842296A
(zh)
|
2015-09-21 |
2025-10-28 |
垂林克生物技术有限公司 |
用于合成5’-加帽rna的组合物和方法
|
|
JP7033535B2
(ja)
|
2016-01-12 |
2022-03-10 |
スクイーズ バイオテクノロジーズ カンパニー |
複合体の細胞内送達
|
|
WO2017155937A1
(en)
|
2016-03-07 |
2017-09-14 |
Actinium Pharmaceuticals, Inc. |
Stabilized radiolabeled anti-cd45 immunoglobulin compositions
|
|
CN109715196A
(zh)
|
2016-06-13 |
2019-05-03 |
转矩医疗股份有限公司 |
用于促进免疫细胞功能的组合物和方法
|
|
EP3523323A4
(en)
*
|
2016-10-07 |
2020-06-17 |
Board of Regents, The University of Texas System |
T-CELLS WITH EXPRESSION OF MEMBRANE-ANCHORED IL-12 FOR THE TREATMENT OF CANCER
|
|
HUE066460T2
(hu)
|
2016-10-26 |
2024-08-28 |
Iovance Biotherapeutics Inc |
A kriokonzervált tumor infiltráló limfociták restimulációja
|
|
KR20190105568A
(ko)
|
2016-11-10 |
2019-09-17 |
넥타르 테라퓨틱스 |
종양의 면역 요법적 치료 방법
|
|
MX2019007963A
(es)
|
2017-01-06 |
2019-10-21 |
Iovance Biotherapeutics Inc |
Expansion de linfocitos infiltrantes de tumor (til) con agonistas de la superfamilia de recptor de factor de necrosis tumoral (tnfrsf) y combinaciones terapeuticas de til- y agonistas de tnfrsf.
|
|
KR102619747B1
(ko)
|
2017-01-10 |
2023-12-29 |
넥타르 테라퓨틱스 |
Tlr 효현제 화합물의 다중-아암 중합체 컨쥬게이트 및 관련 면역 요법적 치료 방법
|
|
JOP20190224A1
(ar)
*
|
2017-03-29 |
2019-09-26 |
Iovance Biotherapeutics Inc |
عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
|
|
JP7285220B2
(ja)
*
|
2017-05-18 |
2023-06-01 |
モデルナティエックス インコーポレイテッド |
連結したインターロイキン－１２（ｉｌ１２）ポリペプチドをコードするポリヌクレオチドを含む脂質ナノ粒子
|
|
EP3634437A4
(en)
*
|
2017-05-19 |
2020-11-18 |
Case Western Reserve University |
COMPOSITIONS AND METHODS FOR EX VIVO EXPANSION OF NATURAL KILLER CELLS AND THEIR THERAPEUTIC USES
|
|
MY206158A
(en)
|
2017-05-24 |
2024-12-02 |
Novartis Ag |
Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
|
|
JP2020530280A
(ja)
|
2017-07-03 |
2020-10-22 |
トルク セラピューティクス， インコーポレイテッド |
免疫刺激性融合分子およびその使用
|
|
KR20240141853A
(ko)
|
2017-08-03 |
2024-09-27 |
신톡스, 인크. |
자가면역 질환의 치료를 위한 사이토카인 접합체
|
|
WO2019136459A1
(en)
*
|
2018-01-08 |
2019-07-11 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
|
EP3749770B9
(en)
|
2018-02-09 |
2025-12-17 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Tethered interleukin-15 and interleukin-21
|
|
CA3090795A1
(en)
*
|
2018-02-13 |
2019-08-22 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists
|
|
WO2019210131A1
(en)
*
|
2018-04-27 |
2019-10-31 |
Iovance Biotherapeutics, Inc. |
Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
MY210603A
(en)
*
|
2018-11-05 |
2025-10-01 |
Iovance Biotherapeutics Inc |
Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
|
US12611427B2
(en)
*
|
2018-11-05 |
2026-04-28 |
Iovance Biotherapeutics, Inc. |
Treatment of NSCLC patients refractory for anti-PD-1 antibody
|
|
CA3123392A1
(en)
*
|
2018-12-19 |
2020-06-25 |
Iovance Biotherapeutics, Inc. |
Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof
|
|
EP3923974A4
(en)
|
2019-02-06 |
2023-02-08 |
Synthorx, Inc. |
IL-2 CONJUGATES AND METHODS OF USE THEREOF
|
|
SG11202110810WA
(en)
|
2019-03-29 |
2021-10-28 |
Torque Therapeutics Inc |
Immunotherapeutic compositions and use thereof
|
|
US20210038684A1
(en)
|
2019-06-11 |
2021-02-11 |
Alkermes Pharma Ireland Limited |
Compositions and Methods for Cancer Immunotherapy
|
|
WO2021050789A1
(en)
*
|
2019-09-10 |
2021-03-18 |
Obsidian Therapeutics, Inc. |
Ca2-il15 fusion proteins for tunable regulation
|